New funding round pumps life into Cardioxyl's HNO heart failure candidates
This article was originally published in Scrip
Executive Summary
Cardioxyl Pharmaceuticals raised $28 million in a Series B venture funding round to finance development of its second-generation nitroxyl (HNO) donor programs for the treatment of acute and chronic heart failure, but it plans to advance a preclinical asset rather than the therapeutic candidate for which it has completed a Phase IIa clinical trial.